Skip to content

Recursion Pharmaceuticals

US · RXRX #2649 by market cap Listed 2021
2.45 -0.27 -9.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Quant vs Street three independent views, side by side

StockVane factor grade
D
Momentum strategy signal
Strong Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 4 analysts

Buy
Avg price target 6.63 +170.6%
Price target rangecurrent 2.45
Low5.90
Avg6.63
High8.00
Buy 50% Hold 50% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-04 BofA Securities -- Hold 6.00
2026-10-19 Needham -- Buy 8.00
2026-10-16 BofA Securities -- Hold 6.00
2026-10-16 Morgan Stanley -- Hold 5.90
2026-09-21 BofA Securities -- Hold --
2026-09-15 J.P. Morgan -- Buy --
2026-08-17 Morgan Stanley -- Hold 5.30
2026-08-12 BofA Securities -- Hold 6.00
2026-08-07 BofA Securities -- Hold 6.00
2026-08-05 TD Cowen -- Hold --
2026-08-05 Needham -- Buy 8.00
2026-05-14 Morgan Stanley -- Hold 5.50
2026-05-13 BofA Securities -- Hold 6.00
2026-05-07 BofA Securities -- Hold 6.00
2026-05-07 Needham -- Buy 8.00
2026-05-06 TD Cowen -- Hold --
2026-04-30 J.P. Morgan -- Buy 10.00
2026-04-14 Needham -- Buy 8.00
2026-02-25 TD Cowen -- Hold --
2026-02-25 BofA Securities -- Hold 6.00
2026-02-25 Needham -- Buy 8.00
2026-01-14 BofA Securities -- Hold 7.00
2026-01-12 BofA Securities -- Hold 7.00
2026-01-06 BofA Securities -- Hold 7.00
2025-12-17 J.P. Morgan -- Buy 11.00

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-02 After close ±10.93% -3.92% (in line)
2026/Q2 2026-08-05 -- ±8.09% -4.23% (in line)
2026/Q1 2026-05-06 -- ±8.09% +1.78% (in line)
2025/Q4 2026-02-25 -- ±7.60% +6.80% (in line)
2025/Q3 2025-11-05 -- ±10.60% -0.80% (in line)
2025/Q2 2025-08-05 -- ±13.93% -4.66% (in line)
2025/Q1 2025-05-05 -- ±16.77% -16.58% (in line)
2024/Q4 2025-02-28 -- ±15.97% -2.09% (in line)
2024/Q3 2024-11-06 After close ±14.48% -0.57% (in line)
2024/Q2 2024-08-08 -- ±22.81% +4.24% (in line)
2024/Q1 2024-05-09 After close ±13.75% -0.46% (in line)
2023/Q4 2024-02-27 After close ±26.20% -16.62% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:59:48 · For reference only, not investment advice and not tailored to your situation.

Recursion Pharmaceuticals discussion 0 comments

Add a comment